Opinion
Video
Marcia Brose, MD, examines data from the COSMIC-311 study, emphasizing the importance of promptly initiating second-line therapy for patients who have progressed on first-line treatments.
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress